Meeting Updates Refine Approaches Toward Urothelial Carcinoma
AstraZeneca's Imfinzi records double bladder cancer failure, endangering first nod and dual-IO case | Fierce Pharma
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options - Cancer Treatment Reviews
ESMO Virtual Congress 2020: A Phase 3, Randomized, Open-Label Study (DANUBE) First Line Durvalumab with or without Tremelimumab vs Standard of Care Chemotherapy in Patients with Unresectable, Locally Advanced or Metastatic Urothelial
The Korean Journal of Internal Medicine
Is Danube Pharmaceuticals Inc. late reporting EU clinical trials?
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. - ppt download
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Management of metastatic bladder cancer - Cancer Treatment Reviews
DANUBE Trial - UROONCO Bladder Cancer
Klinar | News
Continued) Key clinical trials' efficacy data of ICIs in patients with... | Download Scientific Diagram
Assessing the magnitude of reporting bias in trials of homeopathy: a cross-sectional study and meta-analysis | BMJ Evidence-Based Medicine
Cancers | Free Full-Text | Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma | HTML
DANUBE Trial - UROONCO Bladder Cancer
AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV
Biomarkers for immunotherapy in bladder cancer: a moving target | Journal for ImmunoTherapy of Cancer
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
EAU 2021: DANUBE Post-Hoc Analysis: Outcomes for Durvalumab with or Without Tremelimumab by Cisplatin Eligibility and PD-L1 Biomarker Status in Metastatic Urothelial Carcinoma
Daniel P. Petrylak | New Targets for Advanced Bladder Cancer
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
